At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 160 enrolled
Drug / intervention
2 DAA +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt
In Brief
A Phase 3 clinical trial evaluating 2 DAA and RBV for HCV and 2 related conditions. Completed, enrolled 160 participants.
Detailed Summary
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHCV, Hepatitis C Infection, Genotype 4
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartNov 2014
Primary CompletionAug 2016
TodayJul 2026
First PostedSep 25, 2014
Enrollment StartNov 4, 2014
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.8 years ago
Interventions
2 DAAdrug
ABT-450/r/ABT-267 tablets
RBVdrug
Ribavirin tablets